



International Conference on Clinical PET-CT and Molecular Imaging (IPET 2015): PET-CT in the Era of Multimodality Imaging and Image-Guided Therapy


5 – 9 October 2015
IAEA Headquarters, Vienna, Austria


Organized by the IAEA  **IAEA**
International Atomic Energy Agency
Since 1957


MDACC MD Anderson Cancer Center


In cooperation with:


 Singapore General Hospital (SGH)


 American College of Nuclear
Medicine (ACNM)


 Society of Nuclear Medicine and
Molecular Imaging (SNMMI)


 Arab Society of Nuclear Medicine
(ARSNM)


 Society of Radiopharmaceutical
Sciences (SRS)


 Asia Oceania Federation of Nuclear
Medicine and Biology (AOFNMB)


 World Association of
Radiopharmaceutical and Molecular
Therapy (WARMTH)


 Asian School of Nuclear Medicine
(ASNM)


 World Federation of Nuclear
Medicine and Biology (WFNMB)


 Asian Regional Cooperative Council
for Nuclear Medicine (ARCCNM)

 World Molecular Imaging Society
(WMIS)


 Australian and New Zealand Society
of Nuclear Medicine (ANZSNM)


 British Nuclear Medicine Society (BNMS)


 Canadian Association of Nuclear
Medicine (CANM)

 European Association of Nuclear
Medicine (EANM)

 European Federation of Organisations
in Medical Physics (EFOMP)

 European Society of Radiology (ESR)

 International Organization for Medical
Physics (IOMP)

 International Society of Radiolabeled
Blood Elements (ISORBE)

*International Conference on Clinical PET-CT and Molecular Imaging (IPET 2015): PET-CT in the Era of Multimodality
Imaging and Image-Guided Therapy*

BOOK OF ABSTRACTS

IAEA-CN-232

The material in this book has been supplied by the authors and has not been edited. The views expressed remain the responsibility of the named authors and do not necessarily reflect those of the government of the designating Member State(s). The IAEA cannot be held responsible for any material reproduced in the book.

IAEA-CN-232/227

Development of Rituximab Radioimmunoconjugates as PET-Radiopharmaceuticals

D. Gjorgieva Ackova¹, K. Smilkov¹, P. Makreski², T. Stafilov²,
E. Janevik-Ivanovska¹

¹ Department of Pharmacy, Faculty of Medical Sciences, University Goce Delcev - Stip, FYR Macedonia

² Department of Chemistry, Faculty of Natural Sciences and Mathematics, University "Ss. Cyril and Methodius"- Skopje, FYR Macedonia

Corresponding Author: darinka.gorgieva@ugd.edu.mk

Background: Positron emission tomography (PET) has a growing use in medical decision making and management of patients. To further apply the unique properties of PET, more clinically validated PET-radiopharmaceuticals are required and subsequently new and better radiochemical preparation methods are under development. With respect to radiochemistry development, most efforts have been made with the use of ¹¹C and ¹⁸F as radionuclides. Also, labeling methods development stimulates the use of different radiometals as ⁶⁸Ga, ⁸⁹Zr and ⁶⁴Cu for clinical use. These radionuclides have their specific characteristics with respect to half-life, positron energy (resolution), positron abundance and availability. Depending on the biological target of interest and the properties of the PET-radiopharmaceutical the proper radionuclide should be selected.

For the treatment and diagnosis of malignancies, various radiolabeled monoclonal antibodies have also been developed. Rituximab selectively binds with high affinity to the CD20 antigen (human B-lymphocyte restricted differentiation antigen, Bp35), which is expressed on B-lymphocytes and on >90 % of B cell non-Hodgkin lymphomas (NHL). These properties make the CD20 receptor a suitable target for radiotherapy/diagnostic purposes.

Methodology: After promising results (in vitro and in vivo studies) that we obtained in an investigation performed with ¹⁷⁷Lu-rituximab immunoconjugates intended for NHL therapy, in order to obtain ⁶⁸Ga anti-CD20 radioimmunoconjugates for use in PET studies, different bifunctional chelating agents-anti-CD20 conjugates (BFCA-rituximab) were assessed for preliminary chemical characterization. Rituximab, conjugated with three different BFCA, p-SCN-Bn-DOTA, p-SCN-Bn-DTPA and 1B4M-DTPA in form of freeze-dried preparation, was subjected to characterization and determination of secondary structure (which is mandatory for protein-based radiopharmaceuticals), quality parameters (purity, integrity, fragmentation and aggregation of the antibody), and average number of BFCA attached with employment of different analytical techniques such as Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF-MS), Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE), Fourier Transform Infrared (FT-IR) and Raman Spectroscopy.

Results: The results demonstrate that after lyophilisation, diluted rituximab immunoconjugates remain stable. No modification of its chemo-physical characteristics, no aggregation, and preservation of antibody secondary structure were observed. Binding of an average 6.1 (p-SCN-Bn-DOTA), 8.8 (p-SCN-Bn-DTPA) and 8.3 (1B4M-DTPA) molecules per antibody was determined.

Conclusion: The results indicate that the time frame for the practical use of rituximab immunoconjugates can be safely extended using lyophilisation, enabling, for example, safe and longer storage and supporting

the possibility of developing a “ready-to-label” rituximab immunoconjugates for imaging/therapy. Further experiments are still needed in order to demonstrate biological and pharmacological properties. ^{68}Ga -labeled rituximab immunoconjugates may provide PET screening of the therapeutic outcomes following ^{177}Lu therapy. Therefore, developing a kit containing this antibody, intended for ^{68}Ga labeling, will be a part of our future investigation.